Pharming Q2 FY26 operating profit drops 87.96% to US$ 1.3 million; revenue falls 3% to US$ 90.2 million

• Pharming Group 2Q 2026 revenue fell 3% to US$90.2 million, with RUCONEST down 10% to US$72.3 million and Joenja up 40% to US$17.9 million.
• Operating profit slid to US$1.3 million, hit by US$4.9 million inventory impairments and US$1.7 million tied to the planned Évry, France closure.
• Net profit attributable to shareholders declined to US$1.6 million; basic EPS eased to US$0.003.
• Joenja momentum continued, with 132 U.S. patients on paid therapy as of June 30; first European launch in Germany followed EC authorization.
• 2026 revenue guidance cut to US$375 million-US$395 million, while operating expense guidance improved to US$315 million-US$320 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.